Disclosures Managing Bronchiolitis: Just Stand There or Do I have - - PDF document

disclosures
SMART_READER_LITE
LIVE PREVIEW

Disclosures Managing Bronchiolitis: Just Stand There or Do I have - - PDF document

5/17/13 Disclosures Managing Bronchiolitis: Just Stand There or Do I have nothing to disclose Something? Michele Long, MD Associate Clinical Professor Pediatric Hospitalist Case: Emma does Emma need a CXR? Emma is a 4 month old


slide-1
SLIDE 1

 5/17/13  1

Managing Bronchiolitis: Just Stand There or Do Something?

Michele Long, MD Associate Clinical Professor Pediatric Hospitalist

Disclosures

I have nothing to disclose

Case: Emma

 Emma is a 4 month old who is brought to your AM

clinic by Mom. She has a 3 day history of rhinorrhea and a 1 day history of cough. She has had no fever and is taking PO well. On exam she appears well hydrated. She has retractions that clear when she coughs and diffuse expiratory wheezing on exam. She is breathing faster than normal per Mom. You count her respiratory rate at

  • 50. O2 saturation is 97%.

 Her Mom is very concerned…

…does Emma need a CXR?

  • A. Yes to help with diagnosis
  • B. Yes because Mom is so concerned
  • C. No it is not necessary for diagnosis
  • D. No the risks outweigh the benefits
slide-2
SLIDE 2

 5/17/13  2

Bronchiolitis

Most common lower respiratory tract infection in infants

At least 1 in 7 normal infants will develop symptomatic bronchiolitis before age one

Cardinal pathophysiologic features:

 Increased mucous production  Edema and necrosis of small airway epithelial cells  Acute inflammation  Air-trapping

Symptoms

Upper resp infection

 Rhinitis, Congestion

Lower resp infection

 Tachypnea  Cough  Wheezing  Crackles  Nasal flaring  Accessory muscle use  Fever in only 30%

Emma has bronchiolitis

 Clinically consistent with mild presentation  AAP Bronchiolitis Guidelines for CXR

“Clinicians should diagnose bronchiolitis and assess disease severity on the basis of history and physical examination. Clinicians should not routinely order laboratory and radiologic studies for diagnosis”

Note: CXR in bronchiolitis is between 20% and 89%

* “Diagnosis and Management of Bronchiolitis” Pediatrics 2006

CXR for bronchiolitis?

 Only 2 films missed by ED had findings of concern

without other warning sign (like hypoxia or severe respiratory distress)

 One lobar PNA found by radiologist, not ED (RSV+)  31 Children in the study were hospitalized (11%) Schuh S et al J Peds 2007 Adapted from Alverson, Hasbro Children’s

slide-3
SLIDE 3

 5/17/13  3

Emma Continued

 Emma and her mom leave clinic. Later that evening

Emma is brought to the emergency department for fast breathing and poor PO intake.

 In the emergency department, she appears well

hydrated, RR 55, and her oxygen saturation is 94%. Rest of exam unchanged (retractions that clear when she coughs and diffuse expiratory wheezing on exam). She drinks ½ a bottle.

 What would you do next?

What would you do?

  • A. Oxygen
  • B. Bronchodilator trial
  • C. Single-dose dexamethasone
  • D. Suction
  • E. Observe

2006 AAP guidelines

 Oxygen: Warranted if Pulse ox < 90%  Bronchodilator: Consider trial; continue

  • nly if documented clinical response

 No routine steroids  No routine antibiotics  No routine chest physiotherapy

slide-4
SLIDE 4

 5/17/13  4

The bronchodilator story

 Helpful: Schweich et al & Schuh et al improvement

in O2 sat and clinical score after 2 albuterol treatments

 Equivocal/not helpful: Klassen et al noted improved

clinical scores at 30 minutes – not sustained beyond 1 hour. Gadomski et al saw no benefit Inpatient by Dobson et al saw no benefit

 Meta-analysis (Flores et al) with no change in

length of stay

Bronchodilators: 2006

 AAP Bronchiolitis Guideline*

“Bronchodilators should not be used routinely in the management of bronchiolitis. A carefully monitored trial …is an option…and should be continued only if there is a documented positive clinical response to the trial using an

  • bjective means of evaluation

 Rate of bronchodilator use is as high as 70% * Diagnosis and Management of Bronchiolitis. Pediatrics 2006

Summary of Studies

Study Year Where # Bronchodilator Helps? Schweich 92 OP/ED <50 Y, Short-term Schuch 90 OP/ED <50 Y, Short-term Klassen 91 OP/ED <100 Y short term Gadomski 94 ED <100 No Dobson 98 IP <100 No Flores 97 IP Meta No AAP 06 IP/OP OK to trial Cochrane 10 IP/OP No

Reasons for avoiding

Pharmacology: infants don’t have well- developed bronchial wall smooth muscle

Pathophysiology: primary cause of wheezing secretion- related

Side effects: tachycardia, tremors

Cost

slide-5
SLIDE 5

 5/17/13  5

Take home

Cochrane- Gadomski et al 2010: “Bronchodilators produce small short-term improvements in [outpatient] clinical scores… However, given their high cost, adverse effects and lack of effect on oxygen saturation and other

  • utcomes…bronchodilators cannot be recommended

for routine management of first-time wheezers who present with…bronchiolitis, in either inpatient or

  • utpatient settings.”

Controversy: hypertonic saline

Study Type N Prep (vs. NS) Results Mandelberg 03 IP 52 3%+ epi 1 day Length Of Stay Tal 02 IP 41 3%+ epi 0.9 day  LOS Kuzik 07 IP 96 3% 0.9 day  LOS Luo 10 IP 93 3%+ alb 1.4 day  LOS Luo 10 IP 126 3% 1.6 day  LOS Grewal 09 ED 46 3%+ epi No diff p 2 doses Anil 10 ED 186 3%+ alb or epi No diff p 2 hr Kuzik 10 ED 81 3%+ alb No diff p 3 doses Al-Ansari 10 Obs 187 3% or 5% + epi Improved CSS day 2 Sarrell 02 OP 65 3%+ terb Improved CSS day 2-5

 Alverson and Ralston, Contemp Peds 2011

Wanting to Do Something

While limited data supports many bronchiolitis interventions, there are times providers still ‘intervene’ or ‘test’

 Parental insistence  Standard of care for location (ED), medico-legal  Fear of change  Peer/community pressure  Supervisor preference

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

slide-6
SLIDE 6

 5/17/13  6

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

slide-7
SLIDE 7

 5/17/13  7

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

slide-8
SLIDE 8

 5/17/13  8

PHM Choosing Wisely

Adapted from Monash & Le, UCSF Grand Rounds 2013

!"#$%&"'()'&*+),%&'-(."/'-0+,&.#&*+.1(')#&2.%+&3#*"401.*-%)(&-,%+4-&& "'&5'"#*+."1.%.,6

!"#$%&"'()*$+,'$&,-(".#$/*'"#,("(.,'$"&/,(%&(012-$/"'(,3"4$&"#$%&("&+(0"#$,&#(1$-#%.2(5%.(+$")&%-$-(%5("-#14"("&+(6.%&/1$%'$#$-($&(#1,(0,+$"#.$/( 0%0*'"#$%&7(8*'#$0',(-#*+$,-(1"9,(,-#"6'$-1,+('$4$#,+(/'$&$/"'(*#$'$#2(%5(/1,-#(."+$%)."01-(5%.(0"#$,&#-(:$#1("-#14"(%.(6.%&/1$%'$#$-7(;4$--$%&(%5(#1,(( *-,(%5(/1,-#(."+$%)."012(:$''(.,+*/,(/%-#-<(6*#(&%#(/%40.%4$-,(+$")&%-#$/("//*."/2("&+(/".,7

!"#$%&'"3%.#)17&3,)&5'"#*+"(.1-%"',&.#&*+.1(')#&2.%+&5'"#*+."1.%.,6

=*6'$-1,+()*$+,'$&,-(+%(&%#("+9%/"#,(#1,(.%*#$&,(*-,(%5(6.%&/1%+$'"#%.-($&(0"#$,&#-(:$#1(6.%&/1$%'$#$-7(>%40.,1,&-$9,(.,9$,:-(%5(#1,('$#,."#*.,(1"9,(

  • $-('$4$#,+(+,4%&-#."#$%&(%5(/',".($40"/#(%5(6.%&/1%+$'"#%.(#1,."02(*0%&(#1,(/%*.-,(%5(+$-,"-,7(?++$#$%&"''2<(0.%9$+,.-(-1%*'+(/%&-$+,.(#1,(0%#,&#$"'(

$40"/#(%5("+9,.-,(,9,&#-(*0%&(#1,(0"#$,&#7

!"#$%&3,)&,7,%)4.*&*"'%.*",%)'".(,&.#&*+.1(')#&3#()'&8&7)-',&"9&-/)&& 2.%+&-#&3#*"401.*-%)(&1"2)'&'),0.'-%"'7&%'-*%&.#9)*%."#6

=*6'$-1,+()*$+,'$&,-(.,/%44,&+(#1"#(/%.#$/%-#,.%$+(4,+$/"#$%&-(&%#(6,(*-,+(.%*#$&,'2($&(#1,(4"&"),4,&#(%5(6.%&/1$%'$#$-7(@*.#1,.4%.,<("++$#$%&"'(

  • ,300'),,."#&%+)'-076
  • (
  • :$#1("/$+(-*00.,--$%&(#1,."027
  • (

( %.(:,''(+%/*4,&#,+7

3 1 2 5 4

  • !"#$%&'(")(*"+,$&-.(/%0$#$1%(2(:)(.-%'.*&;",0.%-1&<)(.*.#)

=.>)&?+.#/,&:+7,.*.-#,&&

  • #(&:-%.)#%,&@+"31(&A3),%."#

http://www.choosingwisely.org

QI Approach

 Consensus  Measure current  Define a shared goal (achievable)  Intervention  Re-measure  Modify intervention

10 20 30 40 50 60 70 80

Bronchodilators CXR Steroids Chest PT Mean use (2009) Target

VIP Inpatient Data

slide-9
SLIDE 9

 5/17/13  9

Summary

 Current best evidence does not support ordering

CXR’s or routine use of bronchodilators in uncomplicated bronchiolitis

 Hypertonic Saline shows promise but further

evidence is needed

 Good hand washing and avoiding cigarette smoke

are among the best evidence-supported advice we can provide patients

 Changing practice patterns takes time and may be

more effective with QI approaches and if we commit to ‘Choosing Wisely’

Acknowledgements

 Tim Kelly MD  Karen Sun MD  Brad Monash MD  Brian Alverson MD  Emily Whitgob MD

Key References and Resources

Choosing Wisely- Pediatric Hospital Medicine guidelines. Feb 2011 www.choosingwisely.org.

American Academy of Pediatrics. Diagnosis and Management of Bronchiolitis, Subcommittee on Diagnosis and Management of

  • Bronchiolitis. Pediatrics. 2006 Oct;118(4):1774-93.

Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database of Systematic Reviews 2010.

Alverson B, Ralston S. Bronchiolitis: focus on hypertonic saline. Contemporary Pediatrics. Feb 2011.

Wright M, Mullett CJ, Piedimonte G. Pharmacologic Management of Acute Bronchiolitis. Ther Clin Risk Manag. 2008 Oct;4(5):895-903.

References and Resources

Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr. 1990;117:633–7.

Schweich PJ, Hurt TL, Walkley EI, et al. The use of nebulized albuterol in wheezing infants. Pediatr Emerg Care. 1992;8:184–8.

Klassen TP, Rowe PC, Sutcliffe T, et al. Randomized trial of salbutamol in acute bronchiolitis. J Pediatr. 1991;118:807– 11.

Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics. 1994;93:907–12.

Dobson JV, Stephens-Groff SM, Mcmahon SR, et al. The use

  • f albuterol in hospitalized infants with bronchiolitis.
  • Pediatrics. 1998;101:361–8.
slide-10
SLIDE 10

 5/17/13  10

References and Resources

Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics. 1997;100:233–9.

Schuh S, Coates AL, Binnie R, Allin T, Goia C, Corey M, et al. Efficacy of oral dexamethasone in outpatients with acute

  • bronchiolitis. J Pediatr 2002;140:27-32.

Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, et al. A multicenter, randomized, controlled trial

  • f dexamethasone for bronchiolitis. N Engl J Med

2007;357:331-9.

Yong JHE et al. A cost effectiveness analysis of omitting radiography in diagnosis of acute bronchiolitis. Pediatric Pulmonology 44:122-127, 2009

References and Resources

Schuh S et al. Evaluation of the Utility of Radiography in Acute Bronchiolitis. J of Pediatrics. 2007;150:429–433.

Von Woensel JB, van Aalderen WM, Kimpen JL. Viral lower respiratory tract infection in infants and young children. BMJ 2003 Jul 5;327(7405):36–40.

PEM Bronchiolitis Blog pemcincinnati.com

AAP Section on Hospital Medicine Listserv

Extra NOTES